Samuel Reich
Chief Executive Officer bei SAB BIOTHERAPEUTICS, INC.
Vermögen: 99 426 $ am 31.03.2024
Profil
Samuel J.
Reich was the founder of Acuity Pharmaceuticals, Inc. (founded in 2002) where he held the title of Vice President-Research & Development from 2002 to 2007.
He is also the founder of Biscayne Pharmaceuticals, Inc. (founded in 2011) where he served as President & Director.
Additionally, he is the founder of Biscayne Neurotherapeutics, Inc. (founded in 2011) where he held the title of Executive Chairman & President from 2011 to 2018.
Mr. Reich's current job(s) include being the Executive Chairman & Chief Executive Officer at SAB Biotherapeutics, Inc. since 2021 and the Executive Chairman at SAB Sciences, Inc.His former job(s) include being the Director, Chief Executive & Financial Officer at Big Cypress Acquisition Corp.
from 2020 to 2021, Executive Vice President at eXegenics, Inc. in 2007, and Executive Vice President-Ophthalmologics at OPKO Health, Inc. from 2007 to 2008.
Mr. Reich's education history includes completing his undergraduate degree at Clark University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.03.2024 | 21 900 ( 0,24% ) | 99 426 $ | 31.03.2024 |
Aktive Positionen von Samuel Reich
| Unternehmen | Position | Beginn |
|---|---|---|
| SAB BIOTHERAPEUTICS, INC. | Chief Executive Officer | 02.02.2024 |
SAB Sciences, Inc.
 SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The private company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Chairman | - |
Ehemalige bekannte Positionen von Samuel Reich
| Unternehmen | Position | Ende |
|---|---|---|
| BIG CYPR | Chief Executive Officer | 22.10.2021 |
Biscayne Neurotherapeutics, Inc.
 Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL. | Founder | 01.10.2018 |
Biscayne Pharmaceuticals, Inc.
 Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL. | Founder | 01.10.2018 |
| OPKO HEALTH, INC. | Corporate Officer/Principal | 01.11.2008 |
| eXegenics, Inc. | Corporate Officer/Principal | 13.06.2007 |
Ausbildung von Samuel Reich
| Clark University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| OPKO HEALTH, INC. | Health Services |
| SAB BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
| eXegenics, Inc. | Health Technology |
Acuity Pharmaceuticals, Inc.
 Acuity Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Acuity Pharmaceuticals, Inc. developed pharmaceutical products. The company used proprietary technology for the treatment and prevention of ophthalmic diseases. It developed drugs for age related macular degeneration and diabetic macular edema. Acuity Pharmaceuticals was founded in 2002 and was headquartered in Philadelphia, PA. | Commercial Services |
Biscayne Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Biscayne Pharmaceuticals, Inc. develops drugs and pharmaceutical products. It offers drugs for CNS disorders such as refractory epilepsy and drug-resistant cancer. The firm also provides cancer therapies that block growth hormone-releasing hormone (GHRH) receptors. The company was founded by Andrew V. Schally and Samuel J. Reich in 2012 and is headquartered in Miami, FL. | Health Technology |
Biscayne Neurotherapeutics, Inc.
Biscayne Neurotherapeutics, Inc. BiotechnologyHealth Technology Biscayne Neurotherapeutics, Inc. engages in the development of novel treatments for epilepsy, pain and other central nervous system (CNS) disorders. The company was founded by Samuel J. Reich on November 15, 2011 and is headquartered in Miami, FL. | Health Technology |
SAB Sciences, Inc.
SAB Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of SAB Biotherapeutics, Inc., SAB Sciences, Inc. operates as a clinical-stage biopharmaceutical development company. The private company is based in Sioux Falls, SD. The company was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton, Christine E. Hamilton. Eddie J. Sullivan has been the CEO since 2014. SAB Sciences was acquired by Big Cypress Acquisition Corp. on October 22, 2021 for $452.48 million. | Health Technology |
Big Cypress Acquisition Corp.
 Big Cypress Acquisition Corp. Financial ConglomeratesFinance Big Cypress Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on November 12, 2020 and is headquartered in Miami Beach, FL. | Finance |
